Benjamin Hohl
CFO & Head of Corporate DevelopmentMr. Benjamin Hohl, also known as Ben, is Chief Financial Officer of Enliven Therapeutics, Inc. since the closing of the Merger on February 23, 2023 and serves as its Head of Corporate Development since July 2023. Mr. Hohl has served as Chief Financial Officer for Enliven since August 2021. Prior to joining Enliven, he was a Healthcare Investment Banker at Goldman Sachs, where he worked for nearly a decade. While at Goldman Sachs, he established himself as a senior leader in the healthcare group, advising biopharmaceutical and life sciences management teams and boards and executing a broad range of strategic and financing transactions from July 2012 to July 2021. He earned a B.A. in Business Economics and Accounting from the University of California, Los Angeles.
Positions
- Company NameEnliven Therapeutics, Inc.Stock CodeELVNPositionCFO & Head of Corporate DevelopmentColleagues
- RARichard A. FairCEO, President & Director
- SSSamuel S. KintzCo-Founder & Head of Pipeline
- HLHelen Louise CollinsChief Medical Officer
- JPJoseph P. LyssikatosCo-Founder & Research Fellow
- RGRishi GuptaIndependent Director
- JBJacob B. BauerIndependent Director
- SGScott GarlandDirector
- MKMika Kakefuda DerynckIndependent Director
